Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2025—The variables that affect coagulation testing are plentiful, from preanalytic to postanalytic. In a CAP course last year, the presenters walked through a handful that are central to patient safety.
July 2025—There are a few approaches to using DNA sequencing for infectious disease diagnosis, from ribosomal amplicon sequencing to sequencing of microbes found in infected body fluids.
July 2025—Seventy-eight percent of those responding to a survey said their institutions have a pathology student interest group, and they said the most effective ways to engage and retain students are hosting regular events; providing mentorship, leadership, and shadowing opportunities; and offering participation incentives. Using social media and online platforms was reported to be less effective. “A surprise in the findings was the student respondents’ desire to have more faculty engagement. So while students may want to start an interest group and are engaged, they have a hard time getting these off the ground if they don’t have faculty support,” says coauthor Kalisha Hill, MD, MBA. “We’re finding that when the faculty are engaged with these student interest groups, they are much more successful.”
July 2025—We report the case of a 75-year-old female who initially presented with a 10-cm left pretibial mass on MRI. A biopsy revealed a high-grade spindle cell sarcoma with myofibroblastic differentiation. PET CT showed intense uptake in osseous lesions at the scapula, vertebral bodies, iliac bones, sacrum, and femoral head. A sacrum biopsy confirmed metastatic spindle cell sarcoma. The patient underwent chemotherapy and radiotherapy. A follow-up CT scan several months later revealed new liver and lung metastases, prompting molecular analysis of the sacrum specimen.
July 2025—What’s new from Roche, Hologic, and Siemens Healthineers, and how they aim to lighten for labs the burden of the workforce shortage. CAP TODAY publisher Bob McGonnagle spoke about these and other things with three company representatives in an online roundtable, and Stan Schofield, Compass Group managing principal, told them what three questions companies must answer to get a laboratory’s business. Their June 2 conversation follows.
June 2025—For a relatively sleepy field of study, heparin-induced thrombocytopenia has produced more than its share of thrills in the past few years. HIT (sometimes called HITT, with the extra “T” denoting thrombosis) gave way to urgent discussions about vaccine-induced immune thrombotic thrombocytopenia, or VITT, at one particularly panicky point in the COVID-19 pandemic. Take another spin of the wheel: “VITT-like” is now primarily used to refer to cases in which patients have received neither heparin nor a vaccine. Even more recently, researchers have identified a new syndrome, referred to as monoclonal gammopathy of thrombotic significance (MGTS). Publications have put this disorder into three groups. “I think this is going to be the biggest thing in the thrombophilia field in a long time,” predicts Anand Padmanabhan, MD, PhD, professor, Mayo Clinic. Unlike HIT and VITT, MGTS is a chronic condition. “It may end up being part of a thrombophilia profile in the coming years.”
June 2025—The Duffy null phenotype, legal matters, and unmet needs in STI testing are three of the topics on offer at the ADLM meeting next month in Chicago.
June 2025—The authors of a recently published study suggest repeating HER2 testing on the excision specimen for the small number of breast cancer biopsies with group two and group four FISH results. The aim of their study was to determine if FISH group two and group four cases change HER2 status after repeated testing on additional specimens.
June 2025—With few FDA-cleared or -approved methods for tumor marker testing in body fluids, it is the laboratory that’s responsible for the tests. “A specimen arrives at your door, and you have to figure out what, if anything, you’re going to do,” said Jonathan Genzen, MD, PhD, MBA.
June 2025—Some years back, I flew south from New England, where I work as an academic cytopathologist, to North Carolina. My destination was an academic medical center where I was to give a talk on fine-needle aspiration biopsies. On my drive from the airport, I detoured to a small city that housed a company that manufactures zippers. There, on the factory floor, I watched newly made zippers exiting from rows of heavy steel machines. I asked myself: How is that like what we do as pathologists?
